Cover Image
市場調查報告書

JAK及PI3k信號傳達途徑相關的治療藥的市場

JAK and PI3K Signaling Pathway Markets

出版商 BCC Research 商品編碼 299706
出版日期 內容資訊 英文 143 Pages
訂單完成後即時交付
價格
Back to Top
JAK及PI3k信號傳達途徑相關的治療藥的市場 JAK and PI3K Signaling Pathway Markets
出版日期: 2014年04月18日 內容資訊: 英文 143 Pages
簡介

JAK(Janus激酶)及PI3k(磷脂肌醇-3-激酶)等複雜的信號傳達途徑相關研究,這數年急速發展。還有對應這些途徑的異常信號的治療藥和抑制劑的分離這點也見到很大的進步。對應JAK和PI3k的細胞信號傳達途徑的治療藥開發的焦點,在骨髓纖維化治療藥ruxolitinib和類風濕性關節炎治療藥tofacitinib的認證後,轉移到癌症株和發炎性疾病,也進行對氣喘,皮膚病,呼吸疾病,眼科疾病等治療藥的研究。信號傳達途徑相關的治療技術的研究,預期將導致癌症和發炎性疾病等為目標的治療藥開發,因為現在這個領域沒有恰當的醫藥品,市場也有大幅成長的可能性。

本報告提供JAK和PI3k抑制劑/治療藥/生物標記的有前途的用途領域討論、全球市場的商機、成為目標疾病、臨床開發的進展等揭示、法規方面的問題和開發新藥現況、各種市場分析、專利的相關分析,再加上主要企業的簡介,為您概述為以下內容。

第1章 簡介

第2章 摘要整理

第3章 概要

  • Janus激酶(JAK)和磷脂肌醇-3-激酶(PI3k)
  • 對應JAK和PI3k的信號傳達治療藥/抑制劑
  • 分類
  • 對應JAK和PI3k的信號傳達生物標記
  • 有可能成為JAK和PI3k治療藥目標的疾病

第4章 法規的諸方面

  • ruxolitinib(INC424)
  • tafacitinib(CP-690,550)
  • 信號傳達系治療藥/抑制劑/生物標記相關法規的整備

第5章 開發新藥

  • 新的動向
  • 共同臨床實驗和今後的動向

第6章 市場分析-信號傳達系治療藥(JAK和PI3k)

  • 各種產品的市場
  • 全球各地區市場
  • 未來有前途的市場
  • 產業結構
  • 主要用途
  • 有前途的應用領域
    • 癌症
    • 發炎性疾病
    • 慢性心臟疾病
    • 其他

第7章 專利分析

  • 2011年∼2013年已批准專利
  • 各種治療藥的專利
  • JAK及PI3k為基礎的治療藥的專利
  • 在各國已批准專利
  • 受讓人狀況

第8章 市場現狀

  • 新的技術與平台
  • 影響市場的要素
  • 促進市場成長的要素
  • 合作/收購

第9章 主要企業簡介

  • ABBVIE INC.
  • AETERNA ZENTARIS INC.
  • AMGEN INC
  • Astellas Pharma Inc.
  • ASTEX PHARMACEUTICALS INC
  • ASTRAZENECA PLC
  • BAYER HEALTHCARE PHARMACEUTICALS
  • CELL THERAPEUTICS INC
  • CURIS INC.
  • 第一三共
  • ELI LILLY AND CO.
  • EXELIXIS INC.
  • GALAPAGOS NV
  • GENENTECH INC
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • INCYTE CORP.
  • INFINITY PHARMACEUTICALS INC.
  • ITALFARMACO S.P.A.
  • JANSSEN BIOTECH INC.
  • MEI PHARMA INC.
  • MERCK & CO. INC.
  • MILLENNIUM
  • NATIONAL CANCER INSTITUTE
  • 日本全藥工業
  • NOVARTIS INTERNATIONAL AG
  • NS PHARMA, INC
  • ONCOTHYREON INC
  • PATHWAY THERAPEUTICS LTD
  • PFIZER
  • PIRAMAL ENTERPRISES LIMITED
  • PORTOLA PHARMACEUTICALS INC
  • RIGEL PHARMACEUTICALS INC.
  • SANOFI ONCOLOGY
  • TEVA PHARMACEUTICALS INDUSTRIES LTD
  • TG THERAPEUTICS INC.
  • VERASTEM INC.
  • VERTEX PHARMACEUTICALS INC
  • WILEX AG
  • XCOVERY HOLDING COMPANY, LLC

第10章 附錄-簡稱

圖表清單

目錄
Product Code: PHM168A

The global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion in 2018 with a compound annual growth rate (CAGR) of 36.8% over the five-year period from 2013 to 2018.

This report provides:

  • An overview of the global market for signal transduction therapies and inhibitors
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018
  • Information on approved products such as Ruxolitnib, as well as others in devlopment
  • Discussion of the regulatory environment which is impacting development
  • Relevant patent analysis
  • Profiles of leading companies in the industry

STUDY OBJECTIVES

The intent of the report carried out by BCC Research was to assess, explore and envisage the market potential of signal transduction therapies and to review the advancement of the several candidates in their clinical developments for therapies concerning the aberrant signals through janus kinase (JAK) and phosphoinositide 3-kinases (PI3K) pathways. The emerging market analysis for the therapies associated with JAK and PI3K deviant cellular signals is brought together from the approved product performance, the notable clinical developments, the judicious collaborations for advancement of successful research, commercialization plans, huge market opportunities, etc.

The report establishes a balanced projection on the budding market of JAK and PI3K based signal transduction therapies with just two products ruxolitinib (Jakafi) and tofacitinib (Xaljanz). Ruxolitinib was approved in November 2011 for myelofibrosis while tofacitinib was approved in November 2012 for rheumatoid arthritis, respectively. The report also projects the future market for the said therapies, candidate details and their clinical development status, biomarker research, market leaders and market shares, profile of leading companies, collaboration and commercialization strategies, technology platforms and new developments, regulatory aspects, patent details, opportunities and challenges, and drivers and factors determining the signal transduction therapies market for JAK and PI3K.

The sales data for ruxolitinib and tofacitinib is secured from the germane sources that comprise the annual reports of the manufacturing companies and other data sources. Market analysis is conducted for the periods from 2011 until 2013. The report also presents the revenue forecast for the year 2018 with a drilled down analysis on the region wise data for North America (U.S. and Canada), Europe and emerging markets for the examined period.

REASONS FOR DOING THIS STUDY

Significant developments have come about in both the understanding of the complexity of signal transduction pathways such as JAK and PI3K over the past couple of years. At the same time, much progress occurred in the isolation of target specific therapies/inhibitors for the abnormal signals in those pathways. The therapies for JAK and PI3K cellular signal pathways predominantly focus on the cancer lines and inflammatory diseases after the approval of ruxolitinib (for myelofibrosis) and tofacitinib (for rheumatoid arthritis). Although other diseases categories like asthma, skin, respiratory and eye disorders are also being explored largely. The report portrays the prospective therapeutic application of the JAK and PI3K inhibitors/therapies/biomarkers from the perspective of their market opportunity, disease targets, clinical development progress, etc.

The growing market of therapies related to JAK and PI3K signal pathways have tremendous opportunity to grow since these therapies have the potential to target diseases like cancer and inflammatory diseases with no appropriate medications so far. The current therapies are capable of reducing the disease burden but cannot cure. Furthermore, there is a growing patient base worldwide for cancers and inflammatory diseases.

SCOPE OF THE STUDY

BCC Research conducted the market evaluation, the global and regional breakdown of sales data, present and prospective application of the therapies, market forecasting, success and challenges, patent details, regulatory facet, clinical developments, market leaders and market share of the maturing market for JAK and PI3K inhibitors/therapies/biomarkers.

The sales data for the global and regional markets is validated for the present and projected values through scientific and statistical analysis. The information regarding the approved products and candidates as well as the technologies/platforms are provided based on their present/prospective application and viability.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest, from ibuprofen to 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL REVENUE OF SIGNAL TRANSDUCTION
  • THERAPIES/INHIBITORS (JAK AND PI3K), THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL REVENUE OF SIGNAL TRANSDUCTION
  • THERAPIES/INHIBITORS (JAK AND PI3K), 2011-2018) ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • JANUS KINASE (JAK) AND PHOSPHOINOSITIDE 3-KINASES (PI3K)
  • SIGNAL TRANSDUCTION THERAPIES/INHIBITORS FOR JAK AND PI3K
    • MECHANISM OF ACTION
      • Janus Kinase Therapies/Inhibitors
      • Phosphoinositide 3-kinases (PI3K) Therapies/Inhibitors
    • APPROVED HISTONE DEACETYLASE INHIBITORS
  • CLASSIFICATION
    • JANUS KINASE (JAK)
      • TABLE 1: CLASSIFICATION OF JANUS KINASE (JAK)
  • PHOSPHOINOSITIDE 3-KINASES (PI3K)
    • TABLE 2: CLASSIFICATION OF PHOSPHOINOSITIDE 3-KINASES (PI3K)
  • JANUS KINASE THERAPIES/INHIBITORS
    • Ruxolitinib (INC424/INCB18424)
      • FIGURE 1: STRUCTURE OF INC424 (RUXOLITINIB)
    • Tofacitinib (CP-690,550)
      • FIGURE 2: STRUCTURE OF CP-690,550 (TOFACITINIB)
    • Baricitinib (INC28050/LY3009104)
      • FIGURE 3: STRUCTURE OF BARICITINIB (INC28050/LY3009104)
    • NS-018
    • Momelotinib (CYT-387)
      • FIGURE 4: STRUCTURE OF MOMELOTINIB (CYT-387)
    • AT9283
      • FIGURE 5: STRUCTURE OF AT9283
    • Pacritinib (SB1518)
      • FIGURE 6: STRUCTURE OF PACRITINIB (SB1518)
    • LY2784544
      • FIGURE 7 STRUCTURE OF LY2784544
    • TG101348 (SAR302503)
      • FIGURE 8: STRUCTURE OF TG101348 (SAR302503)
    • BMS911543
      • FIGURE 9: STRUCTURE OF BMS911543
    • Lestaurtinib (CEP-701)
      • FIGURE 10: STRUCTURE OF LESTAURTINIB (CEP-701)
    • LS104
    • WP1066
      • FIGURE 11: STRUCTURE OF WP1066
    • AG490
      • FIGURE 12: STRUCTURE OF AG490
    • AZD1480
      • FIGURE 13: STRUCTURE OF AZD1480
    • INCB39110
    • INCB47986
  • PHOSPHOINOSITIDE 3-KINASES (PI3K) THERAPIES/INHIBITORS
    • Wortmannin
      • FIGURE 14: STRUCTURE OF WORTMANNIN
    • Perifosine (KRX-0401)
      • FIGURE 15: STRUCTURE OF PERIFOSINE (KRX-0401)
    • LY294002
      • FIGURE 16: STRUCTURE OF LY294002
    • Idelalisib (GS-1101, CAL-101)
      • FIGURE 17: STRUCTURE OF IDELALISIB (GS-1101, CAL-101)
    • PX-866
      • FIGURE 18: STRUCTURE OF PX-866
    • IPI-145
      • FIGURE 19: STRUCTURE OF IPI-145
    • BKM120
      • FIGURE 20: STRUCTURE OF BKM120
    • Copanlisib (BAY80-6946)
      • FIGURE 21: STRUCTURE OF COPANLISIB (BAY 80-6946)
    • PF-05212384 (PKI-587)
      • FIGURE 22: STRUCTURE OF PF-05212384 (PKI-587)
    • Pictilisib (GDC-0941)
      • FIGURE 23: STRUCTURE OF PICTILISIB (GDC-0941)
    • Dactolisib (BEZ235)
      • FIGURE 24: STRUCTURE OF DACTOLISIB (BEZ235)
    • Apitolisib (GDC-0980)
      • FIGURE 25: STRUCTURE OF APITOLISIB (GDC-0980)
    • ZSTK474
      • FIGURE 26: STRUCTURE OF ZSTK474
    • SAR245409 (XL765)
      • FIGURE 27: STRUCTURE OF SAR245409 (XL765)
    • SAR245408 (XL147)
      • FIGURE 28: STRUCTURE OF APITOLISIB SAR245408 (XL147)
    • BYL719
      • FIGURE 29: STRUCTURE OF APITOLISIB BYL719
  • SIGNAL TRANSDUCTION BIOMARKERS FOR JAK AND PI3K
    • PROSPECTIVE DISEASE TARGETS FOR JAK AND PI3K THERAPIES
      • TABLE 3: SIGNAL TRANSDUCTION THERAPIES/INHIBITORS - PROSPECTIVE DISEASE TARGETS

CHAPTER 4 - REGULATORY ASPECTS

  • RUXOLITINIB (INC424)
    • DOSING INFORMATION
      • Dose Modifications
    • SAFETY INFORMATION
      • Safety of Ruxolitinib in Specific Population
    • RISK OF INFECTION
      • Tuberculosis
      • Progressive Multifocal Leukoencephalopathy (PML)
      • Herpes Zoster
  • TOFACITINIB (CP-690,550)
    • DOSING INFORMATION
      • Dose Modifications
    • SAFETY INFORMATION
      • Safety of Tofacitinib in Specific Populations
    • RISK OF INFECTION
      • Tuberculosis
    • REGULATORY DEVELOPMENTS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS

CHAPTER 5 - NEW DEVELOPMENTS

  • NEW DEVELOPMENTS
    • TABLE 4: NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT
    • TABLE 5: NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) IN COMBINATION WITH OTHER AGENTS
    • TABLE 6: NUMBER OF ONGOING TRIALS FOR MAJOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT AND COMBINATION THERAPY
  • COLLABORATIVE TRIALS AND FUTURE ACTIVITIES

CHAPTER 6 - MARKET ANALYSIS-SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K)

  • MARKET BY THE TYPE
    • TABLE 7: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, THROUGH 2018 ($ MILLIONS)
    • FIGURE 30: GLOBAL MARKET FOR SIGNAL TRANSDUCTION
  • THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2011-2018
    • RUXOLITINIB (INC424, INCB18424)-JANUS KINASE (JAK) INHIBITOR
      • Market Overview
      • Market Revenue
        • TABLE 8: GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 31: GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, 2011-2018 ($ MILLIONS)
    • TOFACITINIB (CP-690,550)-JANUS KINASE (JAK) INHIBITOR
      • Market Overview
      • Market Revenue 75
        • TABLE 9: GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 32: GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, 2011-2018 ($ MILLIONS)
  • MARKET SHARE
    • TABLE 10: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%)
    • FIGURE 33: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%)
  • MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 11: REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 34: REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 12: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS)
      • FIGURE 35: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS)
  • PROSPECTIVE FUTURE MARKET FOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K)
    • INDUSTRY STRUCTURE
    • MARKET LEADERS
      • TABLE 13: LEADING MANUFACTURERS/SUPPLIERS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS
    • MARKET SHARES
      • TABLE 14: MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%)
      • FIGURE 36: MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%)
    • MARKET APPLICATIONS
      • TABLE 15: APPLICATION AREAS OF COMBINATION THERAPY OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (FOR JAK AND PI3K) WITH OTHER THERAPIES
  • MYELOFIBROSIS
  • RHEUMATOID ARTHRITIS
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 16: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, THROUGH 2018 ($ MILLIONS)
      • FIGURE 37: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 17: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%)
      • FIGURE 38: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%)
  • PROSPECTIVE APPLICATION OF SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K)
    • CANCER
    • INFLAMMATORY DISEASES
    • CARDIAC AILMENTS
    • OTHERS

CHAPTER 7 - PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 18: TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013
    • FIGURE 39: TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013
  • PATENTS BY SIGNAL TRANSDUCTION THERAPIES CATEGORY (JAK AND PI3K)
    • TABLE 19: NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS CATEGORY, 2011-2013
    • FIGURE 40: NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS CATEGORY, 2011-2013
  • PATENTS BY SIGNAL TRANSDUCTION THERAPIES TYPE
    • PATENTS BY JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 20: PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • FIGURE 4:1 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • PATENTS BY PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 21: PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • FIGURE 42: PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
  • PATENTS BY COUNTRY
    • JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 22: NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • FIGURE 43: NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • TABLE 23: PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
      • FIGURE 44: PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
    • PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 24: NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • FIGURE 45: NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • TABLE 25: PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
      • FIGURE 46: PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
  • PATENTS BY COMPANY
    • JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 26: NUMBER OF U.S. PATENTS BY COMPANY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 27: NUMBER OF U.S. PATENTS BY COMPANY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
  • PATENTS BY ASSIGNEE
    • JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 28: PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • FIGURE 47: PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 29: PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • FIGURE 48: PATENTS BY ASSGINEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013

CHAPTER 8 - CURRENT SITUATION

  • NEW TECHNOLOGIES AND PLATFORMS IN SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K)
    • SCREENING TECHNOLOGY
    • PYRAMID
    • BIOMARKERS
  • FACTORS AFFECTING THE SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) MARKET
  • CURRENT DRIVERS OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) MARKET
    • COLLABORATIONS/ACQUISITIONS
      • TABLE 30: FUNDINGS IN SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K)

CHAPTER 9 - COMPANY PROFILES

  • ABBVIE INC.
  • AETERNA ZENTARIS INC.
  • AMGEN INC
  • ASTELLAS PHARMA INC.
  • ASTEX PHARMACEUTICALS INC
  • ASTRAZENECA PLC
  • BAYER HEALTHCARE PHARMACEUTICALS
  • CELL THERAPEUTICS INC
  • CURIS INC.
  • DAIICHI SANKYO CO. LTD
  • ELI LILLY AND CO.
  • EXELIXIS INC.
  • GALAPAGOS NV
  • GENENTECH INC
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • INCYTE CORP.
  • INFINITY PHARMACEUTICALS INC.
  • ITALFARMACO S.P.A.
  • JANSSEN BIOTECH INC.
  • MEI PHARMA INC.
  • MERCK & CO. INC.
  • MILLENNIUM
  • NATIONAL CANCER INSTITUTE
  • NIPPON ZENYAKU KOGYO CO., LTD.
  • NOVARTIS INTERNATIONAL AG
  • NS PHARMA, INC
  • ONCOTHYREON INC
  • PATHWAY THERAPEUTICS LTD
  • PFIZER
  • PIRAMAL ENTERPRISES LIMITED
  • PORTOLA PHARMACEUTICALS INC
  • RIGEL PHARMACEUTICALS INC.
  • SANOFI ONCOLOGY
  • TEVA PHARMACEUTICALS INDUSTRIES LTD
  • TG THERAPEUTICS INC.
  • VERASTEM INC.
  • VERTEX PHARMACEUTICALS INC
  • WILEX AG
  • XCOVERY HOLDING COMPANY, LLC

CHAPTER 10 - APPENDIX I-ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), THROUGH 2018 ($ MILLIONS)
    • TABLE 1: CLASSIFICATION OF JANUS KINASE (JAK)
    • TABLE 2: CLASSIFICATION OF PHOSPHOINOSITIDE 3-KINASES (PI3K)
    • TABLE 3: SIGNAL TRANSDUCTION THERAPIES/INHIBITORS - PROSPECTIVE DISEASE TARGETS
    • TABLE 4: NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT
    • TABLE 5: NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) IN COMBINATION WITH OTHER AGENTS
    • TABLE 6: NUMBER OF ONGOING TRIALS FOR MAJOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT AND COMBINATION THERAPY
    • TABLE 7: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 8: GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 9: GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 10: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%)
    • TABLE 11: REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, THROUGH 2018 ($ MILLIONS)
    • TABLE 12: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS)
    • TABLE 13: LEADING MANUFACTURERS/SUPPLIERS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS
    • TABLE 14: MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%)
    • TABLE 15: APPLICATION AREAS OF COMBINATION THERAPY OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (FOR JAK AND PI3K) WITH OTHER THERAPIES
    • TABLE 16: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 17: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%)
    • TABLE 18: TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013
    • TABLE 19: NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, 2011-2013
    • TABLE 20: PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 21: PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 22: NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 23: PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
    • TABLE 24: NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 25: PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
    • TABLE 26: NUMBER OF U.S. PATENTS BY COMPANY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 27: NUMBER OF U.S. PATENTS BY COMPANY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 28: PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 29: PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 30: FUNDINGS IN SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K)

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), 2011-2018) ($ MILLIONS)
    • FIGURE 1: STRUCTURE OF INC424 (RUXOLITINIB)
    • FIGURE 2: STRUCTURE OF CP-690,550 (TOFACITINIB)
    • FIGURE 3: STRUCTURE OF BARICITINIB (INC28050/LY3009104)
    • FIGURE 4: STRUCTURE OF MOMELOTINIB (CYT-387)
    • FIGURE 5: STRUCTURE OF AT9283
    • FIGURE 6: STRUCTURE OF PACRITINIB (SB1518)
    • FIGURE 7: STRUCTURE OF LY2784544
    • FIGURE 8: STRUCTURE OF TG101348 (SAR302503)
    • FIGURE 9: STRUCTURE OF BMS911543
    • FIGURE 10: STRUCTURE OF LESTAURTINIB (CEP-701)
    • FIGURE 11: STRUCTURE OF WP1066
    • FIGURE 12: STRUCTURE OF AG490
    • FIGURE 13: STRUCTURE OF AZD1480
    • FIGURE 14: STRUCTURE OF WORTMANNIN
    • FIGURE 15: STRUCTURE OF PERIFOSINE (KRX-0401)
    • FIGURE 16: STRUCTURE OF LY294002
    • FIGURE 17: STRUCTURE OF IDELALISIB (GS-1101, CAL-101)
    • FIGURE 18: STRUCTURE OF PX-866
    • FIGURE 19: STRUCTURE OF IPI-145
    • FIGURE 20: STRUCTURE OF BKM120
    • FIGURE 21: STRUCTURE OF COPANLISIB (BAY 80-6946)
    • FIGURE 22: STRUCTURE OF PF-05212384 (PKI-587)
    • FIGURE 23: STRUCTURE OF PICTILISIB (GDC-0941)
    • FIGURE 24: STRUCTURE OF DACTOLISIB (BEZ235)
    • FIGURE 25: STRUCTURE OF APITOLISIB (GDC-0980)
    • FIGURE 26: STRUCTURE OF ZSTK474
    • FIGURE 27: STRUCTURE OF SAR245409 (XL765)
    • FIGURE 28: STRUCTURE OF APITOLISIB SAR245408 (XL147)
    • FIGURE 29: STRUCTURE OF APITOLISIB BYL719
    • FIGURE 30: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2011-2018
    • FIGURE 31: GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 32: GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 33: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%)
    • FIGURE 34: REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2011-2018 ($ MILLIONS)
    • FIGURE 35: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS)
    • FIGURE 36: MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%)
    • FIGURE 37: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, 2011-2018 ($ MILLIONS)
    • FIGURE 38: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%)
    • FIGURE 39: TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013
    • FIGURE 40: NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, 2011-2013
    • FIGURE 41: PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/ INHIBITORS/BIOMARKERS, 2011-2013
    • FIGURE 42: PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • FIGURE 43: NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • FIGURE 44: PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
    • FIGURE 45: NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • FIGURE 46: PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
    • FIGURE 47: PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • FIGURE 48: PATENTS BY ASSGINEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Back to Top